Novo Nordisk A/S
NYSE:NVO
Novo Nordisk A/S
NYSE:NVO
Price:
136.04 USD
0.35%
Market Closed
Updated:
May 26, 2024
P/OCF
Price to OCF
Price to OCF
44.3
Current
24.2
Median
17
Industry
Higher
than median
Higher
than industry value
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
P/OCF
=44.3
Market Cap
/
4.1T
Operating Cash Flow
93.4B
All Countries
| Market Cap | P/OCF | ||||
|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
NYSE:NVO
|
4.1T USD | 44.3 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 436.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
767.4B USD | 208.8 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 923.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
353.7B USD | 15.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
328B USD | 22.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
190.6B GBP | 25 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
183.7B CHF | 11.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.5B CHF | 14.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
163.7B USD | 19.1 | |
| FR |
|
Sanofi SA
PAR:SAN
|
112.2B EUR | 10.9 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A
You don't have any saved screeners yet
